Bristol-Myers tests "improved" stress agent in phase II trials
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb Medical Imaging and US firm Adenosine Therapeutics have begun phase II clinical trials of an investigational pharmacologic stress agent for use in cardiac perfusion imaging studies for assessing coronary artery disease (CAD).